BiotechTube
EvolveImmune Therapeutics

EvolveImmune Therapeutics

Branford, United States· Est.
evolveimmune.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $89M

Overview

EvolveImmune Therapeutics is a private, clinical-stage biotech founded in 2019 and based in Branford, Connecticut. The company is developing a pipeline of trispecific T-cell engagers designed with built-in CD2 costimulation via its EVOLVE platform, targeting improved efficacy in solid tumors. Its lead program, EVOLVE104, has entered Phase 1 trials in 2025, and the company has secured a notable partnership with AbbVie. EvolveImmune is positioned in the competitive but high-potential field of next-generation T-cell engagers for oncology.

Oncology

Technology Platform

EVOLVE platform for developing trispecific T-cell engagers with integrated CD2 costimulation to overcome tumor resistance.

Funding History

3
Total raised:$89M
PIPE$37M
Series A$40M
Seed$12M

Opportunities

The large, unmet need in solid tumor immunotherapy presents a multi-billion dollar market.
Success with its integrated costimulation approach could position EvolveImmune's platform as a best-in-class modality for next-generation T-cell engagers.
The partnership with AbbVie provides validation, resources, and a path to expand the pipeline.

Risk Factors

High risk of clinical failure for its novel, unproven mechanism in humans.
Intense competition in the T-cell engager space from larger, better-funded companies.
Reliance on a single lead candidate and partnership for near-term progress, with typical biotech risks of funding and operational execution.

Competitive Landscape

EvolveImmune competes in the rapidly advancing field of multispecific T-cell engagers, facing off against large pharma (e.g., Roche, Amgen, Pfizer) and numerous biotechs. Its key differentiation is the direct integration of CD2 costimulation, competing against other costimulatory approaches (e.g., 4-1BB, ICOS) and trispecific formats from companies like Harpoon Therapeutics and IGM Biosciences.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →